Persistence of Non-Vaccine Oncogenic HPV Serotypes in Quadrivalent HPV2 Vaccinated Women Living with HIV McClymont, Elisabeth; Coutlée, François; Lee, Marette; Albert, Arianne; Raboud, Janet; Walmsley, Sharon; Lipsky, Nancy; Loutfy, Mona; Trottier, Sylvie; Smaill, Fiona; Klein, Marina B.; Yudin, Mark H.; Harris, Marianne; Wobeser, Wendy; Bitnun, Ari; Samson, Lindy; Money, Deborah M.
Objective: To describe prevalent and persistent oncogenic HPV types detected in women living with HIV (WLWH) in Canada, including in women with cervical dyskaryosis, and to determine predictors of type-specific HPV persistence. Methods: 252 women were eligible for this sub-analysis of a prospective vaccine immunogenicity cohort study (2 HPV DNA results, ≥1 cervical cytology result pre60 vaccination). Demographic and clinical data were collected alongside cervical samples for cytology and HPV DNA typing between 2008-2015. Results: Pre-vaccination, HPV16 and HPV52 were the most prevalent oncogenic HPV types. Forty-five percent of participants were infected with ≥1 oncogenic HPV type and one-third of participants had a persistent oncogenic infection. HPV16, 45, and 52 were the most frequently persistent types. Seventeen percent of women had persistent infections with oncogenic HPV types not within currently available vaccines (HPV35/39/51/56/59/68/82). Lower CD4 count significantly predicted HPV persistence (p=0.024). Cervical cytology was 82.9% normal, 2.4% atypical squamous cells of undetermined significance, 11.5% low-grade squamous intraepithelial lesions, and 2.8% high-grade squamous intraepithelial lesions. Conclusion: Unvaccinated WLWH were infected with a wide range of oncogenic HPV types. Our findings highlight the importance of optimal HIV treatment and continued cervical cancer screening as key steps towards global elimination of cervical cancer.
Item Citations and Data
Attribution-NonCommercial 4.0 International